Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) was the target of a significant growth in short interest in January. As of January 31st, there was short interest totalling 19,704,745 shares, a growth of 4.5% from the January 15th total of 18,854,705 shares. Approximately 22.8% of the company’s stock are short sold. Based on an average daily volume of 468,236 shares, the days-to-cover ratio is currently 42.1 days.
A number of institutional investors have recently added to or reduced their stakes in AMPE. Strategic Financial Services Inc acquired a new position in shares of Ampio Pharmaceuticals during the 4th quarter worth approximately $55,000. BlackRock Inc. increased its stake in shares of Ampio Pharmaceuticals by 1.2% in the 4th quarter. BlackRock Inc. now owns 5,449,616 shares of the specialty pharmaceutical company’s stock worth $2,152,000 after acquiring an additional 63,190 shares during the last quarter. Courier Capital LLC increased its stake in shares of Ampio Pharmaceuticals by 16.4% in the 4th quarter. Courier Capital LLC now owns 354,973 shares of the specialty pharmaceutical company’s stock worth $140,000 after acquiring an additional 50,000 shares during the last quarter. Noven Financial Group Inc. acquired a new stake in shares of Ampio Pharmaceuticals in the 4th quarter worth $49,000. Finally, Rhumbline Advisers grew its holdings in shares of Ampio Pharmaceuticals by 54.9% during the 4th quarter. Rhumbline Advisers now owns 111,833 shares of the specialty pharmaceutical company’s stock worth $44,000 after purchasing an additional 39,640 shares during the period.
Ampio Pharmaceuticals stock traded up $0.02 during trading hours on Monday, reaching $0.61. The stock had a trading volume of 624,986 shares, compared to its average volume of 688,410. Ampio Pharmaceuticals has a 52 week low of $0.35 and a 52 week high of $3.89.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability.
Featured Story: Why is Cost of Capital Important?
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.